<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21980373</article-id><article-id pub-id-type="pmc">3181256</article-id><article-id pub-id-type="publisher-id">PONE-D-11-07292</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0025003</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Clinical Research Design</subject><subj-group><subject>Clinical Trials</subject></subj-group></subj-group><subj-group><subject>Drugs and Devices</subject><subj-group><subject>Clinical Pharmacology</subject></subj-group></subj-group><subj-group><subject>Global Health</subject></subj-group><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Neglected Tropical Diseases</subject><subj-group><subject>Soil-Transmitted Helminths</subject></subj-group></subj-group><subj-group><subject>Parasitic Diseases</subject><subj-group><subject>Soil-Transmitted Helminths</subject><subject>Taeniasis</subject></subj-group></subj-group><subj-group><subject>Infectious Disease Control</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Efficacy of Single-Dose and Triple-Dose Albendazole and Mebendazole against Soil-Transmitted Helminths and <italic>Taenia</italic> spp.: A Randomized Controlled Trial</article-title><alt-title alt-title-type="running-head">Efficacy of Anthelmintic Drugs</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Steinmann</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>&#x0002a;</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Utzinger</surname><given-names>J&#x000fc;rg</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Du</surname><given-names>Zun-Wei</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Jin-Yong</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Jia-Xu</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hattendorf</surname><given-names>Jan</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Hui</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Xiao-Nong</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>University of Basel, Basel, Switzerland</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai, People's Republic of China</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Helminthiasis Division, Yunnan Institute of Parasitic Diseases, Simao/Pu'er, People's Republic of China</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Diemert</surname><given-names>David Joseph</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">The George Washington University Medical Center, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>peter.steinmann@unibas.ch</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: PS JU J-XC X-NZ. Performed the experiments: PS Z-WD J-YJ HZ. Analyzed the data: PS JU JH. Contributed reagents/materials/analysis tools: PS JU Z-WD J-YJ HZ JH. Wrote the paper: PS JU JH.</p></fn></author-notes><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>27</day><month>9</month><year>2011</year></pub-date><volume>6</volume><issue>9</issue><elocation-id>e25003</elocation-id><history><date date-type="received"><day>18</day><month>4</month><year>2011</year></date><date date-type="accepted"><day>24</day><month>8</month><year>2011</year></date></history><permissions><copyright-statement>Steinmann et al.</copyright-statement><copyright-year>2011</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>The control of soil-transmitted helminth (STH) infections currently relies on the large-scale administration of single-dose oral albendazole or mebendazole. However, these treatment regimens have limited efficacy against hookworm and <italic>Trichuris trichiura</italic> in terms of cure rates (CR), whereas fecal egg reduction rates (ERR) are generally high for all common STH species. We compared the efficacy of single-dose <italic>versus</italic> triple-dose treatment against hookworm and other STHs in a community-based randomized controlled trial in the People's Republic of China.</p></sec><sec><title>Methodology/Principal findings</title><p>The hookworm CR and fecal ERR were assessed in 314 individuals aged &#x02265;5 years who submitted two stool samples before and 3&#x02013;4 weeks after administration of single-dose oral albendazole (400 mg) or mebendazole (500 mg) or triple-dose albendazole (3&#x000d7;400 mg over 3 consecutive days) or mebendazole (3&#x000d7;500 mg over 3 consecutive days). Efficacy against <italic>T. trichiura</italic>, <italic>Ascaris lumbricoides</italic>, and <italic>Taenia</italic> spp. was also assessed.</p><p>Albendazole cured significantly more hookworm infections than mebendazole in both treatment regimens (single dose: respective CRs 69&#x00025; (95&#x00025; confidence interval [CI]: 55&#x02013;81&#x00025;) and 29&#x00025; (95&#x00025; CI: 20&#x02013;45&#x00025;); triple dose: respective CRs 92&#x00025; (95&#x00025; CI: 81&#x02013;98&#x00025;) and 54&#x00025; (95&#x00025; CI: 46&#x02013;71&#x00025;)). ERRs followed the same pattern (single dose: 97&#x00025; <italic>versus</italic> 84&#x00025;; triple dose: 99.7&#x00025; <italic>versus</italic> 96&#x00025;). Triple-dose regimens outperformed single doses against <italic>T. trichiura</italic>; three doses of mebendazole &#x02013; the most efficacious treatment tested &#x02013; cured 71&#x00025; (95&#x00025; CI: 57&#x02013;82&#x00025;). Both single and triple doses of either drug were highly efficacious against <italic>A. lumbricoides</italic> (CR: 93&#x02013;97&#x00025;; ERR: all &#x0003e;99.9&#x00025;). Triple dose regimens cured all <italic>Taenia</italic> spp. infections, whereas single dose applications cured only half of them.</p></sec><sec><title>Conclusions/Significance</title><p>Single-dose oral albendazole is more efficacious against hookworm than mebendazole. To achieve high CRs against both hookworm and <italic>T. trichiura</italic>, triple-dose regimens are warranted.</p></sec><sec><title>Trial Registration</title><p>
<ext-link ext-link-type="uri" xlink:href="http://www.controlled-trials.com">www.controlled-trials.com</ext-link>
<ext-link ext-link-type="uri" xlink:href="http://www.controlled-trials.com/ISRCTN47375023/ISRCTN47375023">ISRCTN47375023</ext-link>
</p></sec></abstract><counts><page-count count="8"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Hundreds of millions of people are infected with the common soil-transmitted helminths (STHs), namely hookworms (<italic>Ancylostoma duodenale</italic> and <italic>Necator americanus</italic>), <italic>Ascaris lumbricoides</italic> and <italic>Trichuris trichiura</italic>, many by multiple species concurrently <xref rid="pone.0025003-Bethony1" ref-type="bibr">[1]</xref>&#x02013;<xref rid="pone.0025003-Pullan1" ref-type="bibr">[5]</xref>. <italic>Taenia</italic> spp. infections are also widespread <xref rid="pone.0025003-Willingham1" ref-type="bibr">[6]</xref>, <xref rid="pone.0025003-Craig1" ref-type="bibr">[7]</xref>. STHs and taeniasis/cysticercosis belong to the neglected tropical diseases (NTDs) and are responsible for mainly chronic and often inconspicuous morbidity <xref rid="pone.0025003-Ezeamama1" ref-type="bibr">[8]</xref>, <xref rid="pone.0025003-Hotez1" ref-type="bibr">[9]</xref>. Iron-deficiency anemia, malnutrition, and impaired physical and cognitive development have all been attributed to STH infections <xref rid="pone.0025003-Bethony1" ref-type="bibr">[1]</xref>, <xref rid="pone.0025003-Pullan1" ref-type="bibr">[5]</xref>, <xref rid="pone.0025003-Brooker1" ref-type="bibr">[10]</xref>. <italic>Taenia solium</italic> cysticercosis is a major cause of epilepsy and other neurological disorders in developing countries <xref rid="pone.0025003-Garca1" ref-type="bibr">[11]</xref>, <xref rid="pone.0025003-Garcia1" ref-type="bibr">[12]</xref>.</p><p>The current strategy for STH control in highly endemic areas focuses on morbidity control through large-scale administration of single-dose anthelminthics to at-risk populations, particularly school-aged children <xref rid="pone.0025003-Hotez1" ref-type="bibr">[9]</xref>, <xref rid="pone.0025003-WHO1" ref-type="bibr">[13]</xref>, <xref rid="pone.0025003-Hotez2" ref-type="bibr">[14]</xref>. Due to the zoonotic nature of taeniasis/cysticercosis, its control must also include the veterinary sector <xref rid="pone.0025003-Willingham1" ref-type="bibr">[6]</xref>, <xref rid="pone.0025003-Ito1" ref-type="bibr">[15]</xref>&#x02013;<xref rid="pone.0025003-OIEWHOFAO1" ref-type="bibr">[17]</xref>. At present, only four drugs are recommended by the World Health Organization (WHO) for treating STH infections <xref rid="pone.0025003-WHO1" ref-type="bibr">[13]</xref>, <xref rid="pone.0025003-Keiser1" ref-type="bibr">[18]</xref>. The global STH control relies on two of them &#x02013; albendazole and mebendazole &#x02013; both benzimidazole carbamates. Albendazole <xref rid="pone.0025003-Horton1" ref-type="bibr">[19]</xref> and mebendazole <xref rid="pone.0025003-Chavarria1" ref-type="bibr">[20]</xref> display a broad spectrum of activity and are administered orally, usually at a single dose of 400 mg and 500 mg, respectively <xref rid="pone.0025003-WHO1" ref-type="bibr">[13]</xref>, <xref rid="pone.0025003-Keiser1" ref-type="bibr">[18]</xref>, <xref rid="pone.0025003-Geary1" ref-type="bibr">[21]</xref>. Children below the age of 1 year and pregnant women in the first trimester of pregnancy are not eligible for treatment <xref rid="pone.0025003-WHO1" ref-type="bibr">[13]</xref>.</p><p>Albendazole and mebendazole have been extensively used worldwide for more than 30 years, both as stand-alone treatments and, more recently, in combination with other drugs, e.g., praziquantel (against schistosomiasis and food-borne trematodiasis) or ivermectin (against lymphatic filariasis) <xref rid="pone.0025003-Hotez1" ref-type="bibr">[9]</xref>, <xref rid="pone.0025003-Lammie1" ref-type="bibr">[22]</xref>&#x02013;<xref rid="pone.0025003-Mohammed1" ref-type="bibr">[24]</xref>. Surprisingly though, only few clinical trials compared the efficacy of albendazole and mebendazole against STHs. Rather, availability, cost, drug donation programs, and policy instead of the local parasite spectra and evidence determine the choice of which anthelminthic drug is deployed. Justification for the indiscriminate use of either drug is derived from high egg reduction rates (ERRs) achieved with both albendazole and mebendazole, and the assumption that morbidity is a function of infection intensity <xref rid="pone.0025003-Albonico1" ref-type="bibr">[25]</xref>, <xref rid="pone.0025003-King1" ref-type="bibr">[26]</xref>. However, a recent meta-analysis of randomized placebo-controlled single-dose drug efficacy trials pointed to a marked superiority of albendazole over mebendazole against hookworm, high efficacy (in terms of cure rate [CR]) of both drugs against <italic>A. lumbricoides</italic>, and disappointing efficacy of either drug against <italic>T. trichiura</italic>
<xref rid="pone.0025003-Keiser1" ref-type="bibr">[18]</xref>. Few data are available regarding ERRs.</p><p>The aim of this randomized controlled trial was to assess the efficacy of standard single-dose <italic>versus</italic> triple-dose oral albendazole and mebendazole against hookworm and other STH infections in a highly endemic but virtually benzimidazole-na&#x000ef;ve population in the People's Republic of China (P.R. China).</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><p>The protocol for this trial and the supporting CONSORT checklist are available as supporting information; see <xref ref-type="supplementary-material" rid="pone.0025003.s001">Protocol S1</xref> and <xref ref-type="supplementary-material" rid="pone.0025003.s002">Checklist S1</xref>.</p><sec id="s2a"><title>Study Area, Study Period, and Participants</title><p>The study was conducted between October and December 2008 in Nongyang, a village located in Menghai county, Yunnan province, P.R. China. Details of the study area, population and epidemiological characteristics, including the prevalence of STHs, <italic>Taenia</italic> spp., and intestinal protozoa, have been described before <xref rid="pone.0025003-Steinmann1" ref-type="bibr">[3]</xref>, <xref rid="pone.0025003-Steinmann3" ref-type="bibr">[27]</xref>, <xref rid="pone.0025003-Li1" ref-type="bibr">[28]</xref>. The local prevalence of each <italic>A. lumbricoides</italic>, hookworm, and <italic>T. trichiura</italic> exceeded 85&#x00025; in a survey conducted in 2006 <xref rid="pone.0025003-Steinmann1" ref-type="bibr">[3]</xref>. Upon completion of the 2006 survey, compound mebendazole (mebendazole 100 mg/tablet&#x0002b;levamisole hydrochloride 25 mg/tablet, 2 tablets per day for 3 consecutive days) was distributed to the village population. No further interventions took place until the present study.</p></sec><sec id="s2b"><title>Ethics</title><p>The study was approved by the Ethics Committee of Basel (no. 294/08) and the Academic Board of the National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention in Shanghai (no. 2008091701). The trial was registered with Current Controlled Trials (identifier: ISRCTN47375023). The study objectives and procedures were discussed with the village head, village committee, and local health care officials who informed the residents. Individuals who were interested to participate signed an informed consent form in Chinese (parents or legal guardians in case of minors aged 5&#x02013;17 years). Upon study completion, albendazole was provided for treatment of study participants found to be infected at evaluation, drop-outs, sick individuals upon recovery, and pregnant women once beyond the first trimester.</p></sec><sec id="s2c"><title>Interventions, Trial Medication, and Outcome Measures</title><p>The trial was designed as a community-based open-label, outcome assessors-blinded randomized controlled trial with four arms: (i) single-dose albendazole (400 mg), (ii) single-dose mebendazole (500 mg), (iii) triple-dose albendazole (3&#x000d7;400 mg, given over 3 consecutive days), and (iv) triple-dose mebendazole (3&#x000d7;500 mg, given over 3 consecutive days). No placebo drugs were given to individuals assigned to single dose treatment (open label).</p><p>Albendazole (Zentel&#x000ae;; lot no 08060407) was commercially obtained from Sino-American Tianjin SmithKline and French Laboratories Ltd., a Chinese joint venture of GlaxoSmithKline Plc. Mebendazole (Vermox&#x000ae;; lot nos. 8CL4F00 and 7CL8900), produced by Johnson &#x00026; Johnson/Janssen-Cilag S.p.A., was provided by the WHO regional office in Hanoi, Vietnam.</p><p>The primary outcome considered was CR against hookworm 3&#x02013;4 weeks following dosing. Changes in hookworm infection intensity, as determined by ERR, and efficacy against <italic>A. lumbricoides</italic> and <italic>T. trichiura</italic> served as secondary outcomes. Additionally, the effects of all four treatment regimens on <italic>Taenia</italic> spp. were assessed.</p></sec><sec id="s2d"><title>Eligibility Criteria and Sample Size</title><p>Eligible for inclusion were all residents of Nongyang aged 5 years and above. The following exclusion criteria were applied: presence of diagnosed or perceived chronic disease or other conditions likely to interfere with anthelminthic treatment (e.g., hypersensitivity to anthelminthics), pregnancy (verbally assessed at enrolment and again before treatment), recent history of anthelminthic treatment, and participation in other trials (within 1 month).</p><p>The intended sample size at enrolment was 370 individuals, based on the following assumptions: a total of 176 individuals (44 in each of the four treatment arms) would be needed to detect differences in the CR following different treatments for the cure of hookworm infections with 80&#x00025; power using a 2-sided statistical test with an &#x003b1;-level of 0.05 and CRs of albendazole and mebendazole against hookworm infections of 75&#x00025; and 45&#x00025;. According to Keiser and Utzinger <xref rid="pone.0025003-Keiser1" ref-type="bibr">[18]</xref>, the respective CRs are 78&#x00025; and 23&#x00025;; the higher estimate for the CR of mebendazole was employed in order to include a safety margin. The local prevalence of hookworm infections was assumed to be 60&#x00025; and compliance was estimated to be 80&#x00025;. Recruitment was to be stopped once 400 individuals had been enrolled.</p></sec><sec id="s2e"><title>Field and Laboratory Procedures</title><p>Families were contacted in batches of 20&#x02013;30 (&#x0223c;80&#x02013;120 potential participants) based on family registry numbers. Interested family members were invited to the local primary school for further information and enrolment. No monetary compensation was offered for participation. Participants answered a short questionnaire investigating demographic and health-related issues, and were given a stool collection container labeled with a unique identifier and their full name. The ability of all study participants to recognize their collection container was determined, and the importance of using the own receptacle emphasized. Each morning, filled containers were collected, and a new container handed out with the aim to obtain two stool samples from each participant.</p><p>Stool samples were forwarded to a nearby laboratory and processed on the collection day. First, samples were visually inspected for adult <italic>A. lumbricoides</italic> and <italic>Taenia</italic> spp. proglottids. Second, two 41.7 mg Kato-Katz thick smears <xref rid="pone.0025003-Katz1" ref-type="bibr">[29]</xref> were prepared from each sample. Depending on the ambient temperature and considering over-clearance of hookworm eggs, slides were read within 30&#x02013;90 min of preparation <xref rid="pone.0025003-Martin1" ref-type="bibr">[30]</xref>. At least 5&#x00025; of the daily diagnoses were cross-checked by the principal investigator. Procedures for the evaluation of the treatment efficacy commenced 3 weeks post-treatment, lasted 2 weeks, and involved all participants given at least one drug dose. The same approach was adhered to as during the baseline survey.</p></sec><sec id="s2f"><title>Randomization</title><p>All participants who had submitted at least one stool sample during the baseline survey were randomly assigned either to the albendazole or the mebendazole arm of the study. In an independent randomization step, single or triple dose treatment using two computer-generated random sequences of 0 and 1 which were aligned with the list of participants in ascending order of their identification numbers. The eligible individuals were neither stratified by age nor sex before randomization.</p></sec><sec id="s2g"><title>Drug Administration</title><p>For each day of treatment, an envelope of the type locally used to hand out drugs was labeled with the name, identification number, and number of treatment, loaded with the appropriate drugs, and sealed. The distribution teams directly observed drug intake after asking about acute health problems and pregnancy status. Study participants had been reminded not to drink alcohol on treatment days and to report emerging health problems to the study physician (a medical doctor from a nearby hospital who visited the village each morning after drug distribution), any member of the research team, or the head of the village. On the second morning &#x02013; 36 hours after the first dosing &#x02013; all participating households were visited and participants actively solicited to report any potential adverse events. Reported health problems were classified by the study physician and graded by severity according to a pre-defined scale.</p></sec><sec id="s2h"><title>Statistical Analysis</title><p>Data were double-entered in EpiData version 3.1 (EpiData Association; Odense, Denmark) or Microsoft&#x000ae; Excel 2002 (Microsoft; Redmond, USA). After removing discrepancies, the datasets were aligned, and the accuracy of the merged database verified against the original data through random cross-checking. All analyses were performed on a per-protocol basis. Only participants with complete datasets were included.</p><p>Baseline and post-treatment prevalences were estimated, and CRs determined for each study arm. The extent of prevalence reductions and differences in CRs between groups were explored, using a 2-sided 2-sample test of proportions, which tests the equality of proportions using large-sample statistics. For each participant, the species-specific helminth infection intensity at baseline and at treatment evaluation was calculated and expressed as eggs per gram of stool (EPG), based on the arithmetic mean of the quadruplicate Kato-Katz thick smear readings, multiplied by a factor 24. Arithmetic and geometric means and ERRs were calculated according to Montresor et al. <xref rid="pone.0025003-Montresor2" ref-type="bibr">[31]</xref>. Confidence limits for the ERR were calculated using a bootstrap re-sampling method with 2000 iterations. Significant treatment group differences were defined by non-overlapping 95&#x00025; confidence limits. For all tests, a <italic>p</italic>-value of 0.05 was considered the limit of statistical significance, and 95&#x00025; confidence intervals (CIs) were calculated as appropriate. Statistical analyses were done in STATA version 10.1 (StataCorp LP; College Station, USA), bootstrap confidence intervals were calculated using R 2.9.1.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Participant Flow and Baseline Characteristics</title><p>As detailed in <xref ref-type="fig" rid="pone-0025003-g001">Figure 1</xref>, at least one stool sample was available from 378 people who were randomly assigned to one of the four treatment arms. Among them, 314 (83&#x00025;) could be included in the final analysis. The composition of all four groups with regard to sex and age was comparable and baseline prevalences of <italic>A. lumbricoides</italic>, <italic>T. trichiura</italic>, hookworm and <italic>Taenia</italic> spp. were 90&#x00025;, 75&#x00025;, 73&#x00025; and 11&#x00025;, respectively, with no differences among the four treatment arms (<xref ref-type="table" rid="pone-0025003-t001">Table 1</xref>).</p><fig id="pone-0025003-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0025003.g001</object-id><label>Figure 1</label><caption><title>Participation and drop-out at various stages in a trial assessing the efficacy of anthelminthic drugs.</title><p>Participation and causes for drop-out at various stages in a randomized controlled trial assessing the efficacy of single-dose <italic>versus</italic> triple-dose albendazole and mebendazole against STH infections and <italic>Taenia</italic> spp. in a Bulang ethnic minority community in Yunnan province, P.R. China in late 2008.</p></caption><graphic xlink:href="pone.0025003.g001"/></fig><table-wrap id="pone-0025003-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0025003.t001</object-id><label>Table 1</label><caption><title>Demographic characteristics of the participants in a trial assessing the efficacy of anthelminthic drugs.</title></caption><alternatives><graphic id="pone-0025003-t001-1" xlink:href="pone.0025003.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">Single-dose albendazole</td><td align="left" rowspan="1" colspan="1">Single-dose mebendazole</td><td align="left" rowspan="1" colspan="1">Triple-dose albendazole</td><td align="left" rowspan="1" colspan="1">Triple-dose mebendazole</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total n (&#x00025;)</td><td align="left" rowspan="1" colspan="1">314 (100)</td><td align="left" rowspan="1" colspan="1">82 (100)</td><td align="left" rowspan="1" colspan="1">81 (100)</td><td align="left" rowspan="1" colspan="1">68 (100)</td><td align="left" rowspan="1" colspan="1">83 (100)</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex: Female n (&#x00025;)</td><td align="left" rowspan="1" colspan="1">151 (48.1)</td><td align="left" rowspan="1" colspan="1">35 (42.7)</td><td align="left" rowspan="1" colspan="1">39 (48.2)</td><td align="left" rowspan="1" colspan="1">36 (52.9)</td><td align="left" rowspan="1" colspan="1">41 (49.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age n (&#x00025;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">- 5&#x02013;14 years</td><td align="left" rowspan="1" colspan="1">42 (13.4)</td><td align="left" rowspan="1" colspan="1">9 (11.0)</td><td align="left" rowspan="1" colspan="1">8 (9.9)</td><td align="left" rowspan="1" colspan="1">14 (20.6)</td><td align="left" rowspan="1" colspan="1">11 (13.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">- 15&#x02013;24 years</td><td align="left" rowspan="1" colspan="1">88 (28.0)</td><td align="left" rowspan="1" colspan="1">26 (31.7)</td><td align="left" rowspan="1" colspan="1">20 (24.7)</td><td align="left" rowspan="1" colspan="1">19 (27.9)</td><td align="left" rowspan="1" colspan="1">23 (27.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">- 25&#x0002b; years</td><td align="left" rowspan="1" colspan="1">184 (58.6)</td><td align="left" rowspan="1" colspan="1">47 (57.3)</td><td align="left" rowspan="1" colspan="1">53 (65.4)</td><td align="left" rowspan="1" colspan="1">35 (51.5)</td><td align="left" rowspan="1" colspan="1">49 (59.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Parasite n (&#x00025;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">- Hookworm (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">228 (72.6; 67.7&#x02013;77.5)</td><td align="left" rowspan="1" colspan="1">55 (67.1)</td><td align="left" rowspan="1" colspan="1">58 (71.6)</td><td align="left" rowspan="1" colspan="1">50 (73.5)</td><td align="left" rowspan="1" colspan="1">65 (78.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>- Ascaris lumbricoides</italic> (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">284 (90.4; 87.2&#x02013;93.7)</td><td align="left" rowspan="1" colspan="1">78 (95.1)</td><td align="left" rowspan="1" colspan="1">71 (87.7)</td><td align="left" rowspan="1" colspan="1">63 (92.6)</td><td align="left" rowspan="1" colspan="1">72 (86.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>- Trichuris trichiura</italic> (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">234 (74.5; 69.7&#x02013;79.3)</td><td align="left" rowspan="1" colspan="1">65 (79.3)</td><td align="left" rowspan="1" colspan="1">63 (77.8)</td><td align="left" rowspan="1" colspan="1">48 (70.6)</td><td align="left" rowspan="1" colspan="1">58 (69.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>- Taenia</italic> spp. (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">33 (10.5; 7.1&#x02013;13.9)</td><td align="left" rowspan="1" colspan="1">10 (12.2)</td><td align="left" rowspan="1" colspan="1">6 (7.4)</td><td align="left" rowspan="1" colspan="1">7 (10.3)</td><td align="left" rowspan="1" colspan="1">10 (12.0)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>Demographic characteristics and baseline helminth prevalence of the study participants in a randomized controlled trial assessing the efficacy of single-dose and triple-dose albendazole <italic>versus</italic> mebendazole against STH infections and <italic>Taenia</italic> spp. in a Bulang ethnic minority community in Yunnan province, P.R. China, stratified by treatment arm.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Efficacy Against Hookworm and Other STHs</title><p>A single dose of albendazole cured 69&#x00025; (95&#x00025; CI: 55&#x02013;81&#x00025;) of the hookworm infections, while single-dose mebendazole only cured 31&#x00025; (95&#x00025; CI: 20&#x02013;45&#x00025;), significantly less (<xref ref-type="table" rid="pone-0025003-t002">Table 2</xref> and <xref ref-type="table" rid="pone-0025003-t003">table 3</xref>). Triple doses of either drug were significantly more efficacious than single-dose regimens, but the difference between the two drugs persisted: triple-dose albendazole cured significantly more hookworm infections (92&#x00025;, 95&#x00025; CI: 81&#x02013;98&#x00025;) than triple-dose mebendazole (58&#x00025;, 95&#x00025; CI: 46&#x02013;71&#x00025;).</p><table-wrap id="pone-0025003-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0025003.t002</object-id><label>Table 2</label><caption><title>Prevalences and cure rates in a trial assessing the efficacy of anthelminthic drugs (hookworm and <italic>Ascaris lumbricoides</italic>).</title></caption><alternatives><graphic id="pone-0025003-t002-2" xlink:href="pone.0025003.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Single-dose albendazole (<italic>n</italic>&#x0200a;=&#x0200a;82)</td><td align="left" rowspan="1" colspan="1">Single-dose mebendazole (<italic>n</italic>&#x0200a;=&#x0200a;81)</td><td align="left" rowspan="1" colspan="1">Triple-dose albendazole (<italic>n</italic>&#x0200a;=&#x0200a;68)</td><td align="left" rowspan="1" colspan="1">Triple-dose mebendazole (<italic>n</italic>&#x0200a;=&#x0200a;83)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Hookworm</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Prevalence at baseline [&#x00025; (n)]</td><td align="left" rowspan="1" colspan="1">67.1 (55)</td><td align="left" rowspan="1" colspan="1">71.6 (58)</td><td align="left" rowspan="1" colspan="1">73.5 (50)</td><td align="left" rowspan="1" colspan="1">78.3 (65)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prevalence after treatment [&#x00025; (n)]</td><td align="left" rowspan="1" colspan="1">20.7 (17)</td><td align="left" rowspan="1" colspan="1">50.6 (41)</td><td align="left" rowspan="1" colspan="1">5.9 (4)</td><td align="left" rowspan="1" colspan="1">36.1 (30)</td></tr><tr><td align="left" rowspan="1" colspan="1">New positives at evaluation</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Cure rate [&#x00025; (95&#x00025; CI)]<sup>excluding new positives at evaluation</sup>
</td><td align="left" rowspan="1" colspan="1">69.1 (55.2&#x02013;80.9)</td><td align="left" rowspan="1" colspan="1">31.0 (19.5&#x02013;44.5)</td><td align="left" rowspan="1" colspan="1">92.0 (80.8&#x02013;97.8)</td><td align="left" rowspan="1" colspan="1">58.5 (45.6&#x02013;70.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Difference between drug-specific cure rates [&#x00025; (95&#x00025; CI)]</td><td align="left" rowspan="1" colspan="1">38.1 (21.0&#x02013;55.1)&#x0002a;&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1">33.5 (19.4&#x02013;47.7)&#x0002a;&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1">Reference</td></tr><tr><td align="left" rowspan="1" colspan="1">Difference single- vs. triple-dose cure rates [&#x00025; (95&#x00025; CI)]</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1">22.9 (8.6&#x02013;37.2)&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1">27.4 (10.5&#x02013;44.3)&#x0002a;&#x0002a;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>Ascaris lumbricoides</italic></bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Prevalence at baseline [&#x00025; (n)]</td><td align="left" rowspan="1" colspan="1">95.1 (78)</td><td align="left" rowspan="1" colspan="1">87.7 (71)</td><td align="left" rowspan="1" colspan="1">92.6 (63)</td><td align="left" rowspan="1" colspan="1">86.7 (72)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prevalence after treatment [&#x00025; (n)]</td><td align="left" rowspan="1" colspan="1">3.7 (3)</td><td align="left" rowspan="1" colspan="1">6.2 (5)</td><td align="left" rowspan="1" colspan="1">2.9 (2)</td><td align="left" rowspan="1" colspan="1">6.0 (5)</td></tr><tr><td align="left" rowspan="1" colspan="1">New positives at evaluation</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Cure rate [&#x00025; (95&#x00025; CI)]<sup>excluding new positives at evaluation</sup>
</td><td align="left" rowspan="1" colspan="1">96.1 (89.1&#x02013;99.2)</td><td align="left" rowspan="1" colspan="1">93.0 (84.3&#x02013;97.7)</td><td align="left" rowspan="1" colspan="1">96.8 (89.0&#x02013;99.6)</td><td align="left" rowspan="1" colspan="1">93.1 (84.5&#x02013;97.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Difference between drug-specific cure rates [&#x00025; (95&#x00025; CI)]</td><td align="left" rowspan="1" colspan="1">3.2(&#x02212;4.1&#x02013;10.5)</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1">3.8 (&#x02212;3.5&#x02013;11.1)</td><td align="left" rowspan="1" colspan="1">Reference</td></tr><tr><td align="left" rowspan="1" colspan="1">Difference single- vs. triple-dose cure rates [&#x00025; (95&#x00025; CI)]</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1">0.7 (&#x02212;5.4&#x02013;6.8)</td><td align="left" rowspan="1" colspan="1">0.1 (&#x02212;8.2&#x02013;8.4)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label/><p>Cure rates following single-dose and triple-dose albendazole <italic>versus</italic> mebendazole against STH infections and <italic>Taenia</italic> spp., and comparisons between treatment arms. &#x0002a; P value&#x0003c;0.05, &#x0002a;&#x0002a; P value&#x0003c;0.01, &#x0002a;&#x0002a;&#x0002a; P value&#x0003c;0.001.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0025003-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0025003.t003</object-id><label>Table 3</label><caption><title>Prevalences and cure rates in a trial assessing the efficacy of anthelminthic drugs (<italic>Trichuris trichiura</italic> and <italic>Taenia</italic> spp.).</title></caption><alternatives><graphic id="pone-0025003-t003-3" xlink:href="pone.0025003.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Single-dose albendazole (<italic>n</italic>&#x0200a;=&#x0200a;82)</td><td align="left" rowspan="1" colspan="1">Single-dose mebendazole (<italic>n</italic>&#x0200a;=&#x0200a;81)</td><td align="left" rowspan="1" colspan="1">Triple-dose albendazole (<italic>n</italic>&#x0200a;=&#x0200a;68)</td><td align="left" rowspan="1" colspan="1">Triple-dose mebendazole (<italic>n</italic>&#x0200a;=&#x0200a;83)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>Trichuris trichiura</italic></bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Prevalence at baseline [&#x00025; (n)]</td><td align="left" rowspan="1" colspan="1">79.3 (65)</td><td align="left" rowspan="1" colspan="1">77.8 (63)</td><td align="left" rowspan="1" colspan="1">70.6 (48)</td><td align="left" rowspan="1" colspan="1">69.9 (58)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prevalence after treatment [&#x00025; (n)]</td><td align="left" rowspan="1" colspan="1">53.7 (44)</td><td align="left" rowspan="1" colspan="1">49.4 (40)</td><td align="left" rowspan="1" colspan="1">32.4 (22)</td><td align="left" rowspan="1" colspan="1">25.3 (21)</td></tr><tr><td align="left" rowspan="1" colspan="1">New positives at evaluation</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">Cure rate [&#x00025; (95&#x00025; CI)]<sup>excluding new positives at evaluation</sup>
</td><td align="left" rowspan="1" colspan="1">33.8 (22.6&#x02013;46.6)</td><td align="left" rowspan="1" colspan="1">39.7 (27.6&#x02013;52.8)</td><td align="left" rowspan="1" colspan="1">56.2 (41.2&#x02013;70.5)</td><td align="left" rowspan="1" colspan="1">70.7 (57.3&#x02013;81.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Difference between drug-specific cure rates [&#x00025; (95&#x00025; CI)]</td><td align="left" rowspan="1" colspan="1">&#x02212;5.8 (&#x02212;22.5&#x02013;10.8)</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1">&#x02212;14.4 (&#x02212;32.7&#x02013;3.8)</td><td align="left" rowspan="1" colspan="1">Reference</td></tr><tr><td align="left" rowspan="1" colspan="1">Difference single- vs. triple-dose cure rates [&#x00025; (95&#x00025; CI)]</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1">22.4 (4.3&#x02013;40.5)&#x0002a;</td><td align="left" rowspan="1" colspan="1">31.0 (14.2&#x02013;47.8)&#x0002a;&#x0002a;&#x0002a;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>Taenia</italic></bold>
<bold> spp.</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Prevalence at baseline [&#x00025; (n)]</td><td align="left" rowspan="1" colspan="1">12.2 (10)</td><td align="left" rowspan="1" colspan="1">7.4 (6)</td><td align="left" rowspan="1" colspan="1">10.3 (7)</td><td align="left" rowspan="1" colspan="1">12.0 (10)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prevalence after treatment [&#x00025; (n)]</td><td align="left" rowspan="1" colspan="1">7.3 (6)</td><td align="left" rowspan="1" colspan="1">4.9 (4)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">1.2 (1)</td></tr><tr><td align="left" rowspan="1" colspan="1">New positives at evaluation</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Cure rate [&#x00025; (95&#x00025; CI)]<sup>excluding new positives at evaluation</sup>
</td><td align="left" rowspan="1" colspan="1">50.0 (18.7&#x02013;81.2)</td><td align="left" rowspan="1" colspan="1">50.0 (11.8&#x02013;88.2)</td><td align="left" rowspan="1" colspan="1">100 (59.0&#x02013;100)</td><td align="left" rowspan="1" colspan="1">100 (69.2&#x02013;100)</td></tr><tr><td align="left" rowspan="1" colspan="1">Difference between drug-specific cure rates [&#x00025; (95&#x00025; CI)]</td><td align="left" rowspan="1" colspan="1">0 (NA)</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1">0 (NA)</td><td align="left" rowspan="1" colspan="1">Reference</td></tr><tr><td align="left" rowspan="1" colspan="1">Difference single- vs. triple-dose cure rates [&#x00025; (95&#x00025; CI)]</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1">50.0 (19.0&#x02013;80.1)&#x0002a;</td><td align="left" rowspan="1" colspan="1">50.0 (10.0&#x02013;90.0)&#x0002a;</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt103"><label/><p>Cure rates following single-dose and triple-dose albendazole <italic>versus</italic> mebendazole against STH infections and <italic>Taenia</italic> spp., and comparisons between treatment arms. &#x0002a; P value&#x0003c;0.05, &#x0002a;&#x0002a; P value&#x0003c;0.01, &#x0002a;&#x0002a;&#x0002a; P value&#x0003c;0.001.</p></fn></table-wrap-foot></table-wrap><p>Triple-dose mebendazole exhibited the highest reduction in <italic>T. trichiura</italic> prevalence (CR: 71&#x00025;), followed by triple-dose albendazole (56&#x00025;). Single dose applications were found to be significantly less efficacious (mebendazole: 40&#x00025;, albendazole: 34&#x00025;). In both cases, the differences between drug-specific CRs were not statistically significant. As expected, both albendazole and mebendazole cleared most of the <italic>A. lumbricoides</italic> infections with observed CRs ranging between 93&#x00025; and 97&#x00025;. The efficacies of albendazole and mebendazole were comparable. Triple-dose treatment tended to be slightly more efficacious than single-dose treatment, but the difference was not statistically significant. For <italic>Taenia</italic> spp., a single dose of either drug cured about one half of the infections; triple-dose administration cured all infections.</p><p>
<xref ref-type="table" rid="pone-0025003-t004">Table 4</xref> and <xref ref-type="table" rid="pone-0025003-t005">5</xref> (and in greater detail the <xref ref-type="supplementary-material" rid="pone.0025003.s003">Figure S1</xref>) show the baseline EPGs and changes following treatment. In general, the efficacy regarding ERRs followed a similar pattern as that of CRs. Albendazole outperformed mebendazole in terms of hookworm ERR, whereas mebendazole tended to be more efficacious against <italic>T. trichiura</italic>. Triple-dose regimens exhibited significantly higher ERRs against both parasites. All treatments resulted in ERRs&#x0003e;99.9&#x00025; against <italic>A. lumbricoides</italic>. The median hookworm egg count in the 228 infected participants was 84 EPG at baseline and 30 EPG in those 92 still infected after treatment. The administration of three doses of albendazole resulted in the highest ERR against hookworm (99.7&#x00025;; 95&#x00025; CI: 99&#x02013;99.9&#x00025;). Single-dose albendazole with an ERR of 97&#x00025; (95&#x00025; CI: 95&#x02013;99&#x00025;) performed as well as triple-dose mebendazole (96&#x00025;, 95&#x00025; CI: 93&#x02013;98&#x00025;). A single dose of mebendazole resulted in an ERR of only 84&#x00025; (95&#x00025; CI: 73&#x02013;90&#x00025;). For <italic>T. trichiura</italic>, the administration of triple doses resulted in an ERR of 97&#x00025; for mebendazole, and 94&#x00025; for albendazole. With ERRs of 83&#x00025; and 77&#x00025;, respectively, single doses performed significantly worse.</p><table-wrap id="pone-0025003-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0025003.t004</object-id><label>Table 4</label><caption><title>Infection intensity and egg reduction rates in a trial assessing the efficacy of anthelminthic drugs (geometric mean).</title></caption><alternatives><graphic id="pone-0025003-t004-4" xlink:href="pone.0025003.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Single-dose albendazole</td><td align="left" rowspan="1" colspan="1">Single-dose mebendazole</td><td align="left" rowspan="1" colspan="1">Triple-dose albendazole</td><td align="left" rowspan="1" colspan="1">Triple-dose mebendazole</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Hookworm [n]</bold>
</td><td align="left" rowspan="1" colspan="1">55</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">65</td></tr><tr><td align="left" rowspan="1" colspan="1">EPG at baseline (geometric mean)</td><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1">73</td><td align="left" rowspan="1" colspan="1">90</td><td align="left" rowspan="1" colspan="1">86</td></tr><tr><td align="left" rowspan="1" colspan="1">EPG after treatment (geometric mean)</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">ERR; difference in geometric mean [&#x00025;; (95&#x00025; CI)]</td><td align="left" rowspan="1" colspan="1">97.3 (95.2&#x02013;98.7)<sup>b</sup>
</td><td align="left" rowspan="1" colspan="1">83.6 (72.9&#x02013;90.3)<sup>a</sup>
</td><td align="left" rowspan="1" colspan="1">99.7 (99.1&#x02013;99.9)<sup>c</sup>
</td><td align="left" rowspan="1" colspan="1">96.4 (93.3&#x02013;98.2)<sup>b</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>Ascaris lumbricoides</italic></bold>
<bold> [n]</bold>
</td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1">71</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">72</td></tr><tr><td align="left" rowspan="1" colspan="1">EPG at baseline (geometric mean)</td><td align="left" rowspan="1" colspan="1">8,442</td><td align="left" rowspan="1" colspan="1">7,855</td><td align="left" rowspan="1" colspan="1">6,485</td><td align="left" rowspan="1" colspan="1">8,435</td></tr><tr><td align="left" rowspan="1" colspan="1">EPG after treatment (geometric mean)</td><td align="left" rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">0.5</td><td align="left" rowspan="1" colspan="1">0.2</td><td align="left" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">ERR; difference in geometric mean [&#x00025;; (95&#x00025; CI)]</td><td align="left" rowspan="1" colspan="1">&#x0003e;99.9 (&#x0003e;99.9&#x02013;100)<sup>a</sup>
</td><td align="left" rowspan="1" colspan="1">&#x0003e;99.9 (&#x0003e;99.9&#x02013;&#x0003e;99.9)<sup>a</sup>
</td><td align="left" rowspan="1" colspan="1">&#x0003e;99.9 (&#x0003e;99.9&#x02013;100)<sup>a</sup>
</td><td align="left" rowspan="1" colspan="1">&#x0003e;99.9 (&#x0003e;99.9&#x02013;&#x0003e;99.9)<sup>a</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>Trichuris trichiura</italic></bold>
<bold> [n]</bold>
</td><td align="left" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">58</td></tr><tr><td align="left" rowspan="1" colspan="1">EPG at baseline (geometric mean)</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">55</td></tr><tr><td align="left" rowspan="1" colspan="1">EPG after treatment (geometric mean)</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">ERR; difference in geometric mean [&#x00025;; (95&#x00025; CI)]</td><td align="left" rowspan="1" colspan="1">76.7 (62.6&#x02013;86.1)<sup>a</sup>
</td><td align="left" rowspan="1" colspan="1">82.5 (71.0&#x02013;89.6)<sup>a,b</sup>
</td><td align="left" rowspan="1" colspan="1">94.0 (89.4&#x02013;96.8)<sup>b,c</sup>
</td><td align="left" rowspan="1" colspan="1">97.3 (94.9&#x02013;98.8)<sup>c</sup>
</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt104"><label/><p>Infection intensities among those infected at baseline expressed as EPG and ERR following single-dose and triple-dose albendazole <italic>versus</italic> mebendazole against STH infections, and comparisons between treatment arms. Different letters (a, b, c) designate significant differences of ERR between treatment arms, defined by non-overlapping 95&#x00025; confidence limits (calculated by bootstrap resampling).</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0025003-t005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0025003.t005</object-id><label>Table 5</label><caption><title>Infection intensity and egg reduction rates in a trial assessing the efficacy of anthelminthic drugs (arithmetic mean).</title></caption><alternatives><graphic id="pone-0025003-t005-5" xlink:href="pone.0025003.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Single-dose albendazole</td><td align="left" rowspan="1" colspan="1">Single-dose mebendazole</td><td align="left" rowspan="1" colspan="1">Triple-dose albendazole</td><td align="left" rowspan="1" colspan="1">Triple-dose mebendazole</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Hookworm [n]</bold>
</td><td align="left" rowspan="1" colspan="1">55</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">65</td></tr><tr><td align="left" rowspan="1" colspan="1">EPG at baseline [median (25&#x00025;&#x02013;75&#x00025;)]</td><td align="left" rowspan="1" colspan="1">78 (30&#x02013;180)</td><td align="left" rowspan="1" colspan="1">84 (36&#x02013;180)</td><td align="left" rowspan="1" colspan="1">84 (30&#x02013;210)</td><td align="left" rowspan="1" colspan="1">102 (30&#x02013;216)</td></tr><tr><td align="left" rowspan="1" colspan="1">EPG after treatment [median (25&#x00025;&#x02013;75&#x00025;) [n]]</td><td align="left" rowspan="1" colspan="1">30 (12&#x02013;43) <xref rid="pone.0025003-OIEWHOFAO1" ref-type="bibr">[17]</xref>
</td><td align="left" rowspan="1" colspan="1">30 (18&#x02013;126) <xref rid="pone.0025003-Olsen2" ref-type="bibr">[41]</xref>
</td><td align="left" rowspan="1" colspan="1">36 (18&#x02013;56) <xref rid="pone.0025003-Steinmann2" ref-type="bibr">[4]</xref>
</td><td align="left" rowspan="1" colspan="1">18 (12&#x02013;72) <xref rid="pone.0025003-Martin1" ref-type="bibr">[30]</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>Ascaris lumbricoides</italic></bold>
<bold> [n]</bold>
</td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1">71</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">72</td></tr><tr><td align="left" rowspan="1" colspan="1">EPG at baseline [median (25&#x00025;&#x02013;75&#x00025;)]</td><td align="left" rowspan="1" colspan="1">9600 (3,576&#x02013;24,504)</td><td align="left" rowspan="1" colspan="1">10,260 (4,476&#x02013;18,744)</td><td align="left" rowspan="1" colspan="1">8736 (2,382&#x02013;22,056)</td><td align="left" rowspan="1" colspan="1">7956 (4,608&#x02013;19,050)</td></tr><tr><td align="left" rowspan="1" colspan="1">EPG after treatment [median (25&#x00025;&#x02013;75&#x00025;) [n]]</td><td align="left" rowspan="1" colspan="1">18 (6&#x02013;396) <xref rid="pone.0025003-Steinmann1" ref-type="bibr">[3]</xref>
</td><td align="left" rowspan="1" colspan="1">1488 (24&#x02013;2,904) <xref rid="pone.0025003-Pullan1" ref-type="bibr">[5]</xref>
</td><td align="left" rowspan="1" colspan="1">384 (18&#x02013;750) <xref rid="pone.0025003-deSilva1" ref-type="bibr">[2]</xref>
</td><td align="left" rowspan="1" colspan="1">6 (6&#x02013;6) <xref rid="pone.0025003-Pullan1" ref-type="bibr">[5]</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>Trichuris trichiura</italic></bold>
<bold> [n]</bold>
</td><td align="left" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">58</td></tr><tr><td align="left" rowspan="1" colspan="1">EPG at baseline [median (25&#x00025;&#x02013;75&#x00025;)]</td><td align="left" rowspan="1" colspan="1">66 (24&#x02013;138)</td><td align="left" rowspan="1" colspan="1">48 (18&#x02013;144)</td><td align="left" rowspan="1" colspan="1">78 (36&#x02013;132)</td><td align="left" rowspan="1" colspan="1">51 (18&#x02013;138)</td></tr><tr><td align="left" rowspan="1" colspan="1">EPG after treatment [median (25&#x00025;&#x02013;75&#x00025;) [n]]</td><td align="left" rowspan="1" colspan="1">48 (18&#x02013;144) [44]</td><td align="left" rowspan="1" colspan="1">39 (18&#x02013;57) <xref rid="pone.0025003-WHO2" ref-type="bibr">[40]</xref>
</td><td align="left" rowspan="1" colspan="1">30 (18&#x02013;78) <xref rid="pone.0025003-Lammie1" ref-type="bibr">[22]</xref>
</td><td align="left" rowspan="1" colspan="1">18 (6&#x02013;30) <xref rid="pone.0025003-Geary1" ref-type="bibr">[21]</xref>
</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt105"><label/><p>Infection intensities among those infected at time of observation expressed as EPG and ERR following single-dose and triple-dose albendazole <italic>versus</italic> mebendazole against STH infections, and comparisons between treatment arms.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c"><title>Adverse Events</title><p>Thirteen study participants (4.1&#x00025;) reported between one and five adverse events following drug administration, mostly in the morning of the third drug distribution day (about 12 hours after the administration of the second dose, if given) and upon active questioning. Four of these individuals were treated with a single dose (3 with mebendazole, 1 with albendazole) while the remaining nine were treated with triple mebendazole (<italic>n</italic>&#x0200a;=&#x0200a;5) or triple albendazole (<italic>n</italic>&#x0200a;=&#x0200a;4). One symptom was reported by nine individuals, two symptoms by two individuals (1 treated with triple albendazole, 1 with triple mebendazole), three symptoms by one individual (triple mebendazole) and five symptoms by one individual (triple mebendazole). Adverse events included headache (<italic>n</italic>&#x0200a;=&#x0200a;3; all mebendazole), abdominal cramps (<italic>n</italic>&#x0200a;=&#x0200a;3; 2 mebendazole, 1 albendazole) and the closely related &#x0201c;full stomach&#x0201d; (<italic>n</italic>&#x0200a;=&#x0200a;2; mebendazole), and waist pain (<italic>n</italic>&#x0200a;=&#x0200a;1; albendazole). Two individuals each reported vomiting, including production of <italic>A. lumbricoides</italic> worms (1 albendazole, 1 mebendazole), diarrhea (2 mebendazole), fatigue (1 albendazole, 1 mebendazole), and chills (2 mebendazole). Vertigo (albendazole), throat pain (albendazole), fever (mebendazole), and a swollen face (mebendazole) were each reported once. None of the study participants requested medical interventions as adverse events were mild and self-limiting. More women than men reported adverse events (ten women among whom four treated with albendazole and six treated with mebendazole <italic>versus</italic> three men; <italic>P</italic>&#x0200a;=&#x0200a;0.046) but there was no significant association between the report of adverse events and age, drug, or number of treatments according to the Fisher's exact test.</p></sec></sec><sec id="s4"><title>Discussion</title><p>This randomized controlled trial comparing the efficacy of single and triple dose albendazole and mebendazole confirmed that single oral albendazole is more efficacious than mebendazole against hookworm infections <xref rid="pone.0025003-Keiser1" ref-type="bibr">[18]</xref>, <xref rid="pone.0025003-Flohr1" ref-type="bibr">[32]</xref>. It also corroborated that triple-dose regimens result in significantly higher CRs than recommended and widely used single-dose regimens <xref rid="pone.0025003-WHO1" ref-type="bibr">[13]</xref>, <xref rid="pone.0025003-Keiser2" ref-type="bibr">[33]</xref>. A single dose of mebendazole only cured 31&#x00025; of the hookworm infections, while the highest CR, after triple albendazole, was 92&#x00025;. Even triple administration of mebendazole was less efficacious than a single dose of albendazole. Keiser and Utzinger's meta-analysis <xref rid="pone.0025003-Keiser1" ref-type="bibr">[18]</xref> estimated a CR of only 15&#x00025; after single-dose mebendazole, and a value comparable to that found in the present study after single-dose albendazole (present study: 69&#x00025;, meta-analysis: 72&#x00025;). With regard to ERRs, all four drug regimens resulted in significant reductions among those infected at baseline. A triple dose of mebendazole was significantly more efficacious than a single dose.</p><p>The number of <italic>T. trichiura</italic> infections in each treatment arm was significantly, though only moderately reduced, in line with previous findings <xref rid="pone.0025003-Keiser1" ref-type="bibr">[18]</xref>, <xref rid="pone.0025003-Keiser2" ref-type="bibr">[33]</xref>, <xref rid="pone.0025003-Knopp1" ref-type="bibr">[34]</xref>. As expected, triple doses resulted in higher CRs than a single dose regardless of the drug. Worryingly, the highest CR observed was only 71&#x00025; following triple-dose mebendazole. Single and triple doses of mebendazole resulted in higher ERRs than the respective number of albendazole administrations. With regard to <italic>A. lumbricoides</italic> infections, high CRs were observed for both drugs even at a single dose; observations that are in line with systematic reviews and meta-analysis <xref rid="pone.0025003-Keiser1" ref-type="bibr">[18]</xref>, <xref rid="pone.0025003-Keiser2" ref-type="bibr">[33]</xref>.</p><p>Attention was paid to enhance the sensitivity of STH diagnosis by examining multiple Kato-Katz thick smears before and after drug administration <xref rid="pone.0025003-Steinmann1" ref-type="bibr">[3]</xref>, <xref rid="pone.0025003-Bergquist1" ref-type="bibr">[35]</xref>, <xref rid="pone.0025003-Knopp2" ref-type="bibr">[36]</xref>. The low number of &#x0201c;new&#x0201d; infections found at treatment evaluation (<xref ref-type="table" rid="pone-0025003-t002">Table 2</xref> and <xref ref-type="table" rid="pone-0025003-t003">table 3</xref>) indicates that a high sensitivity had been achieved despite the rather low density of hookworm and <italic>T. trichiura</italic> eggs. Because of the low <italic>Taenia</italic> spp. prevalence and since the study was not designed to evaluate treatment efficacy against this parasite, the respective results should be interpreted with caution. The conventional indicator for the successful cure of <italic>Taenia</italic> spp. infections &#x02013; i.e., recovery of the scolex &#x02013; is no definitive proof whenever individuals harbor several worms, and is difficult to perform outside an institutional setting. We focused on the presence of proglottids and eggs.</p><p>An open-label trial design was adhered to due to the complexities and high cost for implementing a double-blind trial in a field setting. We are confident that this did not negatively impact on the validity of the results since outcome assessors were blinded. One individual assigned to the triple albendazole group switched to the single-dose group, and in two instances the drug assignment was changed between members of the same family due to an initial mix-up. We used logistic regression to assess if our results were sensitive to the potential effect modifiers age and sex. Age was treated as a categorical variable (categories as in <xref ref-type="table" rid="pone-0025003-t001">Table 1</xref>) and also as a continuous variable (in years). None of the analyses showed noteworthy differences between the crude and adjusted models with respect to the point estimates or CIs of the odds ratios. The sole exception was the treatment regimen (single dose <italic>versus</italic> triple dose) for which adjustment for sex and age showed stronger effects for both drugs in the case of <italic>T. trichiura</italic>.</p><p>The susceptibility of the two human hookworm species to albendazole is known to be unequal, with CRs for the more pathogenic <italic>A. duodenale</italic> higher than that for <italic>N. americanus</italic>
<xref rid="pone.0025003-Horton2" ref-type="bibr">[37]</xref>. Both hookworm species are endemic in P.R. China but the locally predominant species probably is <italic>N. americanus</italic> according to a polymerase chain reaction (PCR)-based <xref rid="pone.0025003-Zhan1" ref-type="bibr">[38]</xref> species identification performed in a neighboring area <xref rid="pone.0025003-Kotze1" ref-type="bibr">[39]</xref>. Multiple-species intestinal helminth infections are common <xref rid="pone.0025003-Steinmann2" ref-type="bibr">[4]</xref> but no associations between species have been found and the high prevalence of multiparasitism in the study population is unlikely to diminish the validity of the findings for other settings.</p><p>Two additional observations are worth discussing. First, the <italic>A. lumbricoides</italic> CR did not differ significantly (p&#x0003e;0.05) between infection-intensity classes as defined by WHO <xref rid="pone.0025003-WHO2" ref-type="bibr">[40]</xref>. Second, the baseline prevalence of <italic>A. lumbricoides</italic> and hookworm was higher among females than males. At evaluation, the difference persisted for hookworm, but had disappeared for <italic>A. lumbricoides</italic>, probably owing to the high CR against the latter parasite. In the case of <italic>T. trichiura</italic>, comparable prevalences were found for males and females at baseline, but treatment with either drug reduced the prevalence in males more markedly than in females.</p><p>The raw data of our randomized controlled trial is provided as supplementary files (<xref ref-type="supplementary-material" rid="pone.0025003.s004">Data S1</xref> and <xref ref-type="supplementary-material" rid="pone.0025003.s005">Codes S1</xref>). In the spirit of trial registration prior to conducting clinical research, of open-access publishing, and of evidence-based medicine, we believe that others might find our data useful (e.g. for subsequent meta-analysis of drugs used against STHs). We hope that other clinical investigators and research groups will follow our example.</p><p>In conclusion, single-dose albendazole and mebendazole are highly efficacious against <italic>A. lumbricoides</italic>, albendazole is superior to mebendazole for treating hookworm, and mebendazole slightly outperforms albendazole with regard to treating <italic>T. trichiura</italic>. To achieve high CRs against hookworm and <italic>T. trichiura</italic> infections, triple dose regimens should be considered. Yet, for <italic>T. trichiura</italic>, even triple doses only resulted in the cure of a bit more than half of the infections, a result corroborating previous reports <xref rid="pone.0025003-Keiser2" ref-type="bibr">[33]</xref>, <xref rid="pone.0025003-Olsen2" ref-type="bibr">[41]</xref>. Triple-dose treatment is commonly deemed unfeasible in the context of large-scale drug administration programs based on logistical and organizational considerations <xref rid="pone.0025003-Reddy1" ref-type="bibr">[42]</xref>, an issue which needs careful attention. To justify rolling out triple dose treatment, the additional efforts and costs required to do so must be weighed against the benefit, i.e., the higher treatment efficacy, and hence the prevention of harm. From a patient perspective, triple dose treatment appeared acceptable in the present study. Our findings therefore underscore the need for discovery and development of novel drugs for the management of trichuriasis <xref rid="pone.0025003-Geary1" ref-type="bibr">[21]</xref>, <xref rid="pone.0025003-Keiser2" ref-type="bibr">[33]</xref>. Until new drugs become available, it is recommended to investigate ways to boost the efficacy of existing anthelminthics, including combination therapy (e.g., albendazole or mebendazole plus ivermectin) <xref rid="pone.0025003-Geary1" ref-type="bibr">[21]</xref>, <xref rid="pone.0025003-Keiser2" ref-type="bibr">[33]</xref>, <xref rid="pone.0025003-Knopp1" ref-type="bibr">[34]</xref> and multiple dosing <xref rid="pone.0025003-Geary1" ref-type="bibr">[21]</xref>, <xref rid="pone.0025003-Keiser2" ref-type="bibr">[33]</xref>. The higher efficacy of triple doses for treating <italic>Taenia</italic> spp. infections further tips the balance in favor of triple dose schedules in certain areas. With regard to large-scale interventions, the present results call for a more nuanced approach than the standard single-dose mono-drug distribution. Indeed, our findings emphasize the need for careful assessment of the locally endemic STHs, and the adaptation of the employed anthelminthic drug regimens to the prevailing situation. In populations primarily parasitized by <italic>A. lumbricoides</italic> and/or hookworm infections, single or &#x02013; in case of a high prevalence or high-intensity hookworm infections &#x02013; triple-dose albendazole might suffice. Mebendazole treatment with one or better three doses should be adopted in areas with a high prevalence of <italic>T. trichiura</italic> (and possibly <italic>A. lumbricoides</italic>), but a lower number of hookworm infections. In areas where all three species are co-endemic, alternation between albendazole and mebendazole as well as co-administration of different anthelminthic drugs should be considered.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0025003.s001"><label>Protocol S1</label><caption><p>
<bold>Trial protocol.</bold>
</p><p>(DOC)</p></caption><media xlink:href="pone.0025003.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0025003.s002"><label>Checklist S1</label><caption><p>
<bold>CONSORT checklist.</bold>
</p><p>(DOC)</p></caption><media xlink:href="pone.0025003.s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0025003.s003"><label>Figure S1</label><caption><p>
<bold>Frequency distribution of baseline EPGs and changes following treatment.</bold>
</p><p>(PNG)</p></caption><media xlink:href="pone.0025003.s003.png"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0025003.s004"><label>Data S1</label><caption><p>
<bold>Raw data of the trial.</bold>
</p><p>(XLS)</p></caption><media xlink:href="pone.0025003.s004.xls"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0025003.s005"><label>Codes S1</label><caption><p>
<bold>Codes to raw data of the trial.</bold>
</p><p>(DOC)</p></caption><media xlink:href="pone.0025003.s005.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank the field and laboratory team for its commitment, and the study participants for their cooperation. We are grateful to the WHO office in Hanoi for providing the mebendazole tablets free of charge.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>PS is supported by the Novartis Foundation through a personal stipend. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>The Stanley Thomas Johnson Foundation (Bern, Switzerland; <ext-link ext-link-type="uri" xlink:href="http://www.johnsonstiftung.ch">www.johnsonstiftung.ch</ext-link>; no relationship with Johnson &#x00026; Johnson/Janssen-Cilag S.p.A.) sponsored the study. PS (grant no. PBBSP3-123193) and JU (project no. PPOOB-102883, PPOOB-119129) acknowledge support from the Swiss National Science Foundation; PS is also supported by the Novartis Foundation. X-NZ is grateful to the Ministry of Science and Technology (grant no. 2007BAC03A02, 2005DKA21104) and the National Important Project on Infectious Diseases (grant no. 2008ZX10004-011) and the United Nations Children's Fund/United Nations Development Programme/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases (grant no. A30298). The funding bodies had no role in study design, data collection, management, analysis and interpretation, decision to publish, or preparation, review or approval of the manuscript.</p></fn></fn-group><ref-list><title>References</title><ref id="pone.0025003-Bethony1"><label>1</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bethony</surname><given-names>J</given-names></name><name><surname>Brooker</surname><given-names>S</given-names></name><name><surname>Albonico</surname><given-names>M</given-names></name><name><surname>Geiger</surname><given-names>SM</given-names></name><name><surname>Loukas</surname><given-names>A</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm.</article-title>
<source>Lancet</source>
<volume>367</volume>
<fpage>1521</fpage>
<lpage>1532</lpage>
<pub-id pub-id-type="pmid">16679166</pub-id></element-citation></ref><ref id="pone.0025003-deSilva1"><label>2</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Silva</surname><given-names>NR</given-names></name><name><surname>Brooker</surname><given-names>S</given-names></name><name><surname>Hotez</surname><given-names>PJ</given-names></name><name><surname>Montresor</surname><given-names>A</given-names></name><name><surname>Engels</surname><given-names>D</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Soil-transmitted helminth infections: updating the global picture.</article-title>
<source>Trends Parasitol</source>
<volume>19</volume>
<fpage>547</fpage>
<lpage>551</lpage>
<pub-id pub-id-type="pmid">14642761</pub-id></element-citation></ref><ref id="pone.0025003-Steinmann1"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Steinmann</surname><given-names>P</given-names></name><name><surname>Du</surname><given-names>ZW</given-names></name><name><surname>Wang</surname><given-names>LB</given-names></name><name><surname>Wang</surname><given-names>XZ</given-names></name><name><surname>Jiang</surname><given-names>JY</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Extensive multiparasitism in a village of Yunnan province, People's Republic of China, revealed by a suite of diagnostic methods.</article-title>
<source>Am J Trop Med Hyg</source>
<volume>78</volume>
<fpage>760</fpage>
<lpage>769</lpage>
<pub-id pub-id-type="pmid">18458311</pub-id></element-citation></ref><ref id="pone.0025003-Steinmann2"><label>4</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Steinmann</surname><given-names>P</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>ZW</given-names></name><name><surname>Zhou</surname><given-names>XN</given-names></name></person-group>
<year>2010</year>
<article-title>Multiparasitism: a neglected reality on global, regional and local scale.</article-title>
<source>Adv Parasitol</source>
<volume>73</volume>
<fpage>21</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="pmid">20627138</pub-id></element-citation></ref><ref id="pone.0025003-Pullan1"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pullan</surname><given-names>R</given-names></name><name><surname>Brooker</surname><given-names>S</given-names></name></person-group>
<year>2008</year>
<article-title>The health impact of polyparasitism in humans: are we under-estimating the burden of parasitic diseases?</article-title>
<source>Parasitology</source>
<volume>135</volume>
<fpage>783</fpage>
<lpage>794</lpage>
<pub-id pub-id-type="pmid">18371242</pub-id></element-citation></ref><ref id="pone.0025003-Willingham1"><label>6</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Willingham</surname><given-names>AL</given-names><suffix>3rd</suffix></name><name><surname>Engels</surname><given-names>D</given-names></name></person-group>
<year>2006</year>
<article-title>Control of <italic>Taenia solium</italic> cysticercosis/taeniosis.</article-title>
<source>Adv Parasitol</source>
<volume>61</volume>
<fpage>509</fpage>
<lpage>566</lpage>
<pub-id pub-id-type="pmid">16735172</pub-id></element-citation></ref><ref id="pone.0025003-Craig1"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Craig</surname><given-names>P</given-names></name><name><surname>Ito</surname><given-names>A</given-names></name></person-group>
<year>2007</year>
<article-title>Intestinal cestodes.</article-title>
<source>Curr Opin Infect Dis</source>
<volume>20</volume>
<fpage>524</fpage>
<lpage>532</lpage>
<pub-id pub-id-type="pmid">17762788</pub-id></element-citation></ref><ref id="pone.0025003-Ezeamama1"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ezeamama</surname><given-names>AE</given-names></name><name><surname>Friedman</surname><given-names>JF</given-names></name><name><surname>Olveda</surname><given-names>RM</given-names></name><name><surname>Acosta</surname><given-names>LP</given-names></name><name><surname>Kurtis</surname><given-names>JD</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Functional significance of low-intensity polyparasite helminth infections in anemia.</article-title>
<source>J Infect Dis</source>
<volume>192</volume>
<fpage>2160</fpage>
<lpage>2170</lpage>
<pub-id pub-id-type="pmid">16288383</pub-id></element-citation></ref><ref id="pone.0025003-Hotez1"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hotez</surname><given-names>PJ</given-names></name><name><surname>Molyneux</surname><given-names>DH</given-names></name><name><surname>Fenwick</surname><given-names>A</given-names></name><name><surname>Kumaresan</surname><given-names>J</given-names></name><name><surname>Ehrlich Sachs</surname><given-names>S</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Control of neglected tropical diseases.</article-title>
<source>N Engl J Med</source>
<volume>357</volume>
<fpage>1018</fpage>
<lpage>1027</lpage>
<pub-id pub-id-type="pmid">17804846</pub-id></element-citation></ref><ref id="pone.0025003-Brooker1"><label>10</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brooker</surname><given-names>S</given-names></name><name><surname>Hotez</surname><given-names>PJ</given-names></name><name><surname>Bundy</surname><given-names>DAP</given-names></name></person-group>
<year>2008</year>
<article-title>Hookworm-related anaemia among pregnant women: a systematic review.</article-title>
<source>PLoS Negl Trop Dis</source>
<volume>2</volume>
<fpage>e291</fpage>
<pub-id pub-id-type="pmid">18820740</pub-id></element-citation></ref><ref id="pone.0025003-Garca1"><label>11</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garc&#x000ed;a</surname><given-names>HH</given-names></name><name><surname>Gonzalez</surname><given-names>AE</given-names></name><name><surname>Evans</surname><given-names>CA</given-names></name><name><surname>Gilman</surname><given-names>RH</given-names></name></person-group>
<year>2003</year>
<article-title>
<italic>Taenia solium</italic> cysticercosis.</article-title>
<source>Lancet</source>
<volume>362</volume>
<fpage>547</fpage>
<lpage>556</lpage>
<pub-id pub-id-type="pmid">12932389</pub-id></element-citation></ref><ref id="pone.0025003-Garcia1"><label>12</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garcia</surname><given-names>HH</given-names></name><name><surname>Moro</surname><given-names>PL</given-names></name><name><surname>Schantz</surname><given-names>PM</given-names></name></person-group>
<year>2007</year>
<article-title>Zoonotic helminth infections of humans: echinococcosis, cysticercosis and fascioliasis.</article-title>
<source>Curr Opin Infect Dis</source>
<volume>20</volume>
<fpage>489</fpage>
<lpage>494</lpage>
<pub-id pub-id-type="pmid">17762782</pub-id></element-citation></ref><ref id="pone.0025003-WHO1"><label>13</label><element-citation publication-type="book">
<collab>WHO</collab>
<year>2006</year>
<source>Preventive chemotherapy in human helminthiasis. Coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers</source>
<publisher-loc>Geneva</publisher-loc>
<publisher-name>World Health Organization</publisher-name>
<fpage>1</fpage>
<lpage>62</lpage>
</element-citation></ref><ref id="pone.0025003-Hotez2"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hotez</surname><given-names>PJ</given-names></name><name><surname>Fenwick</surname><given-names>A</given-names></name><name><surname>Savioli</surname><given-names>L</given-names></name><name><surname>Molyneux</surname><given-names>DH</given-names></name></person-group>
<year>2009</year>
<article-title>Rescuing the bottom billion through control of neglected tropical diseases.</article-title>
<source>Lancet</source>
<volume>373</volume>
<fpage>1570</fpage>
<lpage>1575</lpage>
<pub-id pub-id-type="pmid">19410718</pub-id></element-citation></ref><ref id="pone.0025003-Ito1"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ito</surname><given-names>A</given-names></name><name><surname>Urbani</surname><given-names>C</given-names></name><name><surname>Qiu</surname><given-names>JM</given-names></name><name><surname>Vuitton</surname><given-names>DA</given-names></name><name><surname>Qiu</surname><given-names>DC</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Control of echinococcosis and cysticercosis: a public health challenge to international cooperation in China.</article-title>
<source>Acta Trop</source>
<volume>86</volume>
<fpage>3</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="pmid">12711098</pub-id></element-citation></ref><ref id="pone.0025003-Montresor1"><label>16</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Montresor</surname><given-names>A</given-names></name><name><surname>Palmer</surname><given-names>K</given-names></name></person-group>
<year>2006</year>
<article-title>Taeniasis/cysticercosis trend worldwide and rationale for control.</article-title>
<source>Parasitol Int</source>
<volume>55</volume>
<issue>Suppl.</issue>
<fpage>S301</fpage>
<lpage>303</lpage>
<pub-id pub-id-type="pmid">16337431</pub-id></element-citation></ref><ref id="pone.0025003-OIEWHOFAO1"><label>17</label><element-citation publication-type="book">
<collab>OIE/WHO/FAO</collab>
<year>2005</year>
<article-title>WHO/FAO/OIE guidelines for the surveillance, prevention and control of taeniasis/cysticercosis;</article-title>
<person-group person-group-type="editor"><name><surname>Murrell</surname><given-names>KD</given-names></name></person-group>
<publisher-loc>Paris</publisher-loc>
<publisher-name>World Organization for Animal Health</publisher-name>
<fpage>1</fpage>
<lpage>139</lpage>
</element-citation></ref><ref id="pone.0025003-Keiser1"><label>18</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Keiser</surname><given-names>J</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name></person-group>
<year>2008</year>
<article-title>Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis.</article-title>
<source>JAMA</source>
<volume>299</volume>
<fpage>1937</fpage>
<lpage>1948</lpage>
<pub-id pub-id-type="pmid">18430913</pub-id></element-citation></ref><ref id="pone.0025003-Horton1"><label>19</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Horton</surname><given-names>J</given-names></name></person-group>
<year>2002</year>
<article-title>Albendazole: a broad spectrum anthelminthic for treatment of individuals and populations.</article-title>
<source>Curr Opin Infect Dis</source>
<volume>15</volume>
<fpage>599</fpage>
<lpage>608</lpage>
<pub-id pub-id-type="pmid">12821837</pub-id></element-citation></ref><ref id="pone.0025003-Chavarria1"><label>20</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chavarria</surname><given-names>AP</given-names></name><name><surname>Swartzwelder</surname><given-names>JC</given-names></name><name><surname>Villarejos</surname><given-names>VM</given-names></name><name><surname>Zeledon</surname><given-names>R</given-names></name></person-group>
<year>1973</year>
<article-title>Mebendazole, an effective broad-spectrum anthelmintic.</article-title>
<source>Am J Trop Med Hyg</source>
<volume>22</volume>
<fpage>592</fpage>
<lpage>595</lpage>
<pub-id pub-id-type="pmid">4729739</pub-id></element-citation></ref><ref id="pone.0025003-Geary1"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Geary</surname><given-names>TG</given-names></name><name><surname>Woo</surname><given-names>K</given-names></name><name><surname>McCarthy</surname><given-names>JS</given-names></name><name><surname>Mackenzie</surname><given-names>CD</given-names></name><name><surname>Horton</surname><given-names>J</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Unresolved issues in anthelmintic pharmacology for helminthiases of humans.</article-title>
<source>Int J Parasitol</source>
<volume>40</volume>
<fpage>1</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="pmid">19932111</pub-id></element-citation></ref><ref id="pone.0025003-Lammie1"><label>22</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lammie</surname><given-names>PJ</given-names></name><name><surname>Fenwick</surname><given-names>A</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name></person-group>
<year>2006</year>
<article-title>A blueprint for success: integration of neglected tropical disease control programmes.</article-title>
<source>Trends Parasitol</source>
<volume>22</volume>
<fpage>313</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="pmid">16713738</pub-id></element-citation></ref><ref id="pone.0025003-Olsen1"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Olsen</surname><given-names>A</given-names></name></person-group>
<year>2007</year>
<article-title>Efficacy and safety of drug combinations in the treatment of schistosomiasis, soil-transmitted helminthiasis, lymphatic filariasis and onchocerciasis.</article-title>
<source>Trans R Soc Trop Med Hyg</source>
<volume>101</volume>
<fpage>747</fpage>
<lpage>758</lpage>
<pub-id pub-id-type="pmid">17481681</pub-id></element-citation></ref><ref id="pone.0025003-Mohammed1"><label>24</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mohammed</surname><given-names>KA</given-names></name><name><surname>Haji</surname><given-names>HJ</given-names></name><name><surname>Gabrielli</surname><given-names>AF</given-names></name><name><surname>Mubila</surname><given-names>L</given-names></name><name><surname>Biswas</surname><given-names>G</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Triple co-administration of ivermectin, albendazole and praziquantel in Zanzibar: a safety study.</article-title>
<source>PLoS Negl Trop Dis</source>
<volume>2</volume>
<fpage>e171</fpage>
<pub-id pub-id-type="pmid">18235853</pub-id></element-citation></ref><ref id="pone.0025003-Albonico1"><label>25</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Albonico</surname><given-names>M</given-names></name><name><surname>Allen</surname><given-names>H</given-names></name><name><surname>Chitsulo</surname><given-names>L</given-names></name><name><surname>Engels</surname><given-names>D</given-names></name><name><surname>Gabrielli</surname><given-names>AF</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Controlling soil-transmitted helminthiasis in pre-school-age children through preventive chemotherapy.</article-title>
<source>PLoS Negl Trop Dis</source>
<volume>2</volume>
<fpage>e126</fpage>
<pub-id pub-id-type="pmid">18365031</pub-id></element-citation></ref><ref id="pone.0025003-King1"><label>26</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>King</surname><given-names>CH</given-names></name></person-group>
<year>2010</year>
<article-title>Parasites and poverty: the case of schistosomiasis.</article-title>
<source>Acta Trop</source>
<volume>113</volume>
<fpage>95</fpage>
<lpage>104</lpage>
<pub-id pub-id-type="pmid">19962954</pub-id></element-citation></ref><ref id="pone.0025003-Steinmann3"><label>27</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Steinmann</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>XN</given-names></name><name><surname>Du</surname><given-names>ZW</given-names></name><name><surname>Jiang</surname><given-names>JY</given-names></name><name><surname>Wang</surname><given-names>LB</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Occurrence of <italic>Strongyloides stercoralis</italic> in Yunnan province, China, and comparison of diagnostic methods.</article-title>
<source>PLoS Negl Trop Dis</source>
<volume>1</volume>
<fpage>e75</fpage>
<pub-id pub-id-type="pmid">17989788</pub-id></element-citation></ref><ref id="pone.0025003-Li1"><label>28</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>LH</given-names></name><name><surname>Zhou</surname><given-names>XN</given-names></name><name><surname>Du</surname><given-names>ZW</given-names></name><name><surname>Wang</surname><given-names>XZ</given-names></name><name><surname>Wang</surname><given-names>LB</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Molecular epidemiology of human <italic>Blastocystis</italic> in a village in Yunnan province, China.</article-title>
<source>Parasitol Int</source>
<volume>56</volume>
<fpage>281</fpage>
<lpage>286</lpage>
<pub-id pub-id-type="pmid">17627869</pub-id></element-citation></ref><ref id="pone.0025003-Katz1"><label>29</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Katz</surname><given-names>N</given-names></name><name><surname>Chaves</surname><given-names>A</given-names></name><name><surname>Pellegrino</surname><given-names>J</given-names></name></person-group>
<year>1972</year>
<article-title>A simple device for quantitative stool thick-smear technique in schistosomiasis mansoni.</article-title>
<source>Rev Inst Med Trop S&#x000e3;o Paulo</source>
<volume>14</volume>
<fpage>397</fpage>
<lpage>400</lpage>
</element-citation></ref><ref id="pone.0025003-Martin1"><label>30</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martin</surname><given-names>LK</given-names></name><name><surname>Beaver</surname><given-names>PC</given-names></name></person-group>
<year>1968</year>
<article-title>Evaluation of Kato thick-smear technique for quantitative diagnosis of helminth infections.</article-title>
<source>Am J Trop Med Hyg</source>
<volume>17</volume>
<fpage>382</fpage>
<lpage>391</lpage>
<pub-id pub-id-type="pmid">5690644</pub-id></element-citation></ref><ref id="pone.0025003-Montresor2"><label>31</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Montresor</surname><given-names>A</given-names></name><name><surname>Crompton</surname><given-names>DWT</given-names></name><name><surname>Hall</surname><given-names>A</given-names></name><name><surname>Bundy</surname><given-names>DAP</given-names></name><name><surname>Savioli</surname><given-names>L</given-names></name></person-group>
<year>1998</year>
<source>Guidelines for the evaluation of soil-transmitted helminthiasis and schistosomiasis at community level</source>
<publisher-loc>Geneva</publisher-loc>
<publisher-name>World Health Organization</publisher-name>
<fpage>1</fpage>
<lpage>49</lpage>
</element-citation></ref><ref id="pone.0025003-Flohr1"><label>32</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Flohr</surname><given-names>C</given-names></name><name><surname>Tuyen</surname><given-names>LN</given-names></name><name><surname>Lewis</surname><given-names>S</given-names></name><name><surname>Minh</surname><given-names>TT</given-names></name><name><surname>Campbell</surname><given-names>J</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Low efficacy of mebendazole against hookworm in Vietnam: two randomized controlled trials.</article-title>
<source>Am J Trop Med Hyg</source>
<volume>76</volume>
<fpage>732</fpage>
<lpage>736</lpage>
<pub-id pub-id-type="pmid">17426180</pub-id></element-citation></ref><ref id="pone.0025003-Keiser2"><label>33</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Keiser</surname><given-names>J</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name></person-group>
<year>2010</year>
<article-title>The drugs we have and the drugs we need against major helminth infections Advances in Parasitology</article-title>
<volume>73</volume>
<fpage>197</fpage>
<lpage>230</lpage>
</element-citation></ref><ref id="pone.0025003-Knopp1"><label>34</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Knopp</surname><given-names>S</given-names></name><name><surname>Mohammed</surname><given-names>KA</given-names></name><name><surname>Speich</surname><given-names>B</given-names></name><name><surname>Hattendorf</surname><given-names>J</given-names></name><name><surname>Khamis</surname><given-names>IS</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Albendazole and mebendazole administered alone or in combination with ivermectin against <italic>Trichuris trichiura</italic>: a randomized controlled trial.</article-title>
<source>Clin Infect Dis</source>
<volume>51</volume>
<fpage>1420</fpage>
<lpage>1428</lpage>
<pub-id pub-id-type="pmid">21062129</pub-id></element-citation></ref><ref id="pone.0025003-Bergquist1"><label>35</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bergquist</surname><given-names>R</given-names></name><name><surname>Johansen</surname><given-names>MV</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name></person-group>
<year>2009</year>
<article-title>Diagnostic dilemmas in helminthology: what tools to use and when?</article-title>
<source>Trends Parasitol</source>
<volume>25</volume>
<fpage>151</fpage>
<lpage>156</lpage>
<pub-id pub-id-type="pmid">19269899</pub-id></element-citation></ref><ref id="pone.0025003-Knopp2"><label>36</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Knopp</surname><given-names>S</given-names></name><name><surname>Speich</surname><given-names>B</given-names></name><name><surname>Hattendorf</surname><given-names>J</given-names></name><name><surname>Rinaldi</surname><given-names>L</given-names></name><name><surname>Mohammed</surname><given-names>KA</given-names></name><etal/></person-group>
<year>2011</year>
<article-title>Diagnostic accuracy of Kato-Katz and FLOTAC for assessing anthelmintic drug efficacy.</article-title>
<source>PLoS Negl Trop Dis</source>
<volume>5</volume>
<fpage>e1036</fpage>
<pub-id pub-id-type="pmid">21532740</pub-id></element-citation></ref><ref id="pone.0025003-Horton2"><label>37</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Horton</surname><given-names>J</given-names></name></person-group>
<year>2000</year>
<article-title>Albendazole: a review of anthelmintic efficacy and safety in humans.</article-title>
<source>Parasitology</source>
<volume>121</volume>
<issue>Suppl.</issue>
<fpage>S113</fpage>
<lpage>132</lpage>
<pub-id pub-id-type="pmid">11386684</pub-id></element-citation></ref><ref id="pone.0025003-Zhan1"><label>38</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhan</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Xiao</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>F</given-names></name><name><surname>Hawdon</surname><given-names>JM</given-names></name></person-group>
<year>2001</year>
<article-title>Species-specific identification of human hookworms by PCR of the mitochondrial cytochrome oxidase I gene.</article-title>
<source>J Parasitol</source>
<volume>87</volume>
<fpage>1227</fpage>
<lpage>1229</lpage>
<pub-id pub-id-type="pmid">11695411</pub-id></element-citation></ref><ref id="pone.0025003-Kotze1"><label>39</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kotze</surname><given-names>AC</given-names></name><name><surname>Steinmann</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Du</surname><given-names>ZW</given-names></name><name><surname>Zhou</surname><given-names>XN</given-names></name></person-group>
<year>2011</year>
<article-title>The Effect of Egg Embryonation on Field-Use of a Hookworm Benzimidazole-Sensitivity Egg Hatch Assay in Yunnan Province, People's Republic of China.</article-title>
<source>PLoS Negl Trop Dis</source>
<volume>5</volume>
<fpage>e1203</fpage>
<pub-id pub-id-type="pmid">21738805</pub-id></element-citation></ref><ref id="pone.0025003-WHO2"><label>40</label><element-citation publication-type="journal">
<collab>WHO</collab>
<year>2002</year>
<article-title>Prevention and control of schistosomiasis and soil-transmitted helminthiasis: report of a WHO expert committee.</article-title>
<source>WHO Tech Rep Ser</source>
<volume>912</volume>
<fpage>1</fpage>
<lpage>57</lpage>
</element-citation></ref><ref id="pone.0025003-Olsen2"><label>41</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Olsen</surname><given-names>A</given-names></name><name><surname>Namwanje</surname><given-names>H</given-names></name><name><surname>Nejsum</surname><given-names>P</given-names></name><name><surname>Roepstorff</surname><given-names>A</given-names></name><name><surname>Thamsborg</surname><given-names>SM</given-names></name></person-group>
<year>2009</year>
<article-title>Albendazole and mebendazole have low efficacy against <italic>Trichuris trichiura</italic> in school-age children in Kabale district, Uganda.</article-title>
<source>Trans R Soc Trop Med Hyg</source>
<volume>103</volume>
<fpage>443</fpage>
<lpage>446</lpage>
<pub-id pub-id-type="pmid">19201005</pub-id></element-citation></ref><ref id="pone.0025003-Reddy1"><label>42</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reddy</surname><given-names>M</given-names></name><name><surname>Gill</surname><given-names>SS</given-names></name><name><surname>Kalkar</surname><given-names>SR</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Anderson</surname><given-names>PJ</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Oral drug therapy for multiple neglected tropical diseases: a systematic review.</article-title>
<source>JAMA</source>
<volume>298</volume>
<fpage>1911</fpage>
<lpage>1924</lpage>
<pub-id pub-id-type="pmid">17954542</pub-id></element-citation></ref></ref-list></back></article>